Cloning Technologies for Protein Expression and Purification
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Protein Tagging and Detection with Engineered Self-Assembling Fragments of Green fluorescent Protein
LETTERS Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein Ste´phanie Cabantous, Thomas C Terwilliger & Geoffrey S Waldo Existing protein tagging and detection methods are powerful the same amount of refolded superfolder GFP 1–10. In addition to the but have drawbacks. Split protein tags can perturb protein folding reporter GFP mutations, GFP 1–10 OPT contains S30R, solubility1–4 or may not work in living cells5–7. Green Y145F, I171V and A206V substitutions from superfolder GFP and fluorescent protein (GFP) fusions can misfold8 or exhibit seven new mutations: N39I, T105K, E111V, I128T, K166T, I167V and altered processing9. Fluorogenic biarsenical FLaSH or S205T. This protein is B50% soluble when expressed in E. coli at ReASH10 substrates overcome many of these limitations but 37 1C (data not shown). Ultraviolet-visible spectra of 10 mg/ml require a polycysteine tag motif, a reducing environment and solutions of the nonfluorescent GFP 1–10 OPT lacked the 480 nm cell transfection or permeabilization10. An ideal protein tag absorption band of the red-shifted GFP19 (data not shown), suggest- http://www.nature.com/naturebiotechnology would be genetically encoded, would work both in vivo and ing that the addition of GFP 11 triggers a folding step required to in vitro, would provide a sensitive analytical signal and would generate the cyclized chromophore19. Purified GFP 1–10 OPT, super- not require external chemical reagents or substrates. One way folder GFP and folding reporter GFP were each studied by analytical to accomplish this might be with a split GFP11, but the GFP gel filtration loaded at 10 mg/ml. -
Gene Therapy Glossary of Terms
GENE THERAPY GLOSSARY OF TERMS A • Phase 3: A phase of research to describe clinical trials • Allele: one of two or more alternative forms of a gene that that gather more information about a drug’s safety and arise by mutation and are found at the same place on a effectiveness by studying different populations and chromosome. different dosages and by using the drug in combination • Adeno-Associated Virus: A single stranded DNA virus that has with other drugs. These studies typically involve more not been found to cause disease in humans. This type of virus participants.7 is the most frequently used in gene therapy.1 • Phase 4: A phase of research to describe clinical trials • Adenovirus: A member of a family of viruses that can cause occurring after FDA has approved a drug for marketing. infections in the respiratory tract, eye, and gastrointestinal They include post market requirement and commitment tract. studies that are required of or agreed to by the study • Adeno-Associated Virus Vector: Adeno viruses used as sponsor. These trials gather additional information about a vehicles for genes, whose core genetic material has been drug’s safety, efficacy, or optimal use.8 removed and replaced by the FVIII- or FIX-gene • Codon: a sequence of three nucleotides in DNA or RNA • Amino Acids: building block of a protein that gives instructions to add a specific amino acid to an • Antibody: a protein produced by immune cells called B-cells elongating protein in response to a foreign molecule; acts by binding to the • CRISPR: a family of DNA sequences that can be cleaved by molecule and often making it inactive or targeting it for specific enzymes, and therefore serve as a guide to cut out destruction and insert genes. -
Lecture 3 Types, Biology and Salient Features of Vectors in Recombinant
NPTEL – Bio Technology – Genetic Engineering & Applications MODULE 1- LECTURE 3 TYPES, BIOLOGY AND SALIENT FEATURES OF VECTORS IN RECOMBINANT DNA TECHNOLOGY – PLASMID 1-3.1 Introduction: DNA molecule used for carrying an exogenous DNA into a host organism and facilitates stable integration and replication inside the host system is termed as Vector. Molecular cloning involves series of sequential steps which includes restriction digestion of DNA fragments both target DNA and vector, ligation of the target DNA with the vector and introduction into a host organism for multiplication. Then the fragments resulted after digestion with restriction enzymes are ligated to other DNA molecules that serve as vectors. In general, vectors should have following characteristics: • Capable of replicating inside the host. • Have compatible restriction site for insertion of DNA molecule (insert). • Capable of autonomous replication inside the host (ori site). • Smaller in size and able to incorporate larger insert size. • Have a selectable marker for screening of recombinant organism. 1-3.2 Plasmids: • Plasmids are naturally occurring extra chromosomal double-stranded circular DNA molecules which can autonomously replicate inside bacterial cells. Plasmids range in size from about 1.0 kb to over 250 kb. • Plasmids encode only few proteins required for their own replication (replication proteins) and these proteins encoding genes are located very close to the ori. All the other proteins required for replication, e.g. DNA polymerases, DNA ligase, helicase, etc., are provided by the host cell.Thus, only a small region surrounding Joint initiative of IITs and IISc – Funded by MHRD Page 28 of 84 NPTEL – Bio Technology – Genetic Engineering & Applications the ori site is required for replication. -
Protein Expression and Purification Series
Bio-Rad Explorer™ Protein Expression and Purifi cation Series Catalog Numbers 1665040EDU Centrifugation Purifi cation Process 1665045EDU Handpacked Purifi cation Process 1665050EDU Prepacked Purifi cation Process 1665070EDU Assessment Module explorer.bio-rad.com Please see each individual module for storage conditions. Duplication of any part of this document permitted for classroom use only. Please visit explorer.bio-rad.com to access our selection of language translations for Biotechnology Explorer Kit curricula. For technical service, call your local bio-rad offi ce, or in the U.S., call 1-800-4BIORAD (1-800-424-6723) Protein Expression and Purifi cation Series Dear Educator One of the great promises of the biotechnology industry is the ability to produce biopharmaceuticals to treat human disease. Genentech pioneered the development of recombinant DNA technology to produce products with a practical application. In the mid-1970s, insulin, used to treat diabetics, was extracted from the pancreas glands of swine and cattle that were slaughtered for food. It would take approximately 8,000 pounds of animal pancreas glands to produce one pound of insulin. Rather than extract the protein from animal sources, Genentech engineered bacterial cells to produce human insulin, resulting in the world’s fi rst commercial genetically engineered product. Producing novel proteins in bacteria or other cell types is not simple. Active proteins are often comprised of multiple chains of amino acids with complex folding and strand interactions. Commandeering a particular cell to reproduce the native form presents many challenges. Considerations of cell type, plasmid construction, and purifi cation strategy are all part of the process of developing a recombinant protein. -
Molecular Biology and Applied Genetics
MOLECULAR BIOLOGY AND APPLIED GENETICS FOR Medical Laboratory Technology Students Upgraded Lecture Note Series Mohammed Awole Adem Jimma University MOLECULAR BIOLOGY AND APPLIED GENETICS For Medical Laboratory Technician Students Lecture Note Series Mohammed Awole Adem Upgraded - 2006 In collaboration with The Carter Center (EPHTI) and The Federal Democratic Republic of Ethiopia Ministry of Education and Ministry of Health Jimma University PREFACE The problem faced today in the learning and teaching of Applied Genetics and Molecular Biology for laboratory technologists in universities, colleges andhealth institutions primarily from the unavailability of textbooks that focus on the needs of Ethiopian students. This lecture note has been prepared with the primary aim of alleviating the problems encountered in the teaching of Medical Applied Genetics and Molecular Biology course and in minimizing discrepancies prevailing among the different teaching and training health institutions. It can also be used in teaching any introductory course on medical Applied Genetics and Molecular Biology and as a reference material. This lecture note is specifically designed for medical laboratory technologists, and includes only those areas of molecular cell biology and Applied Genetics relevant to degree-level understanding of modern laboratory technology. Since genetics is prerequisite course to molecular biology, the lecture note starts with Genetics i followed by Molecular Biology. It provides students with molecular background to enable them to understand and critically analyze recent advances in laboratory sciences. Finally, it contains a glossary, which summarizes important terminologies used in the text. Each chapter begins by specific learning objectives and at the end of each chapter review questions are also included. -
Regulation of Transgene Expression in Genetic Immunization
Brazilian Journal of Medical and Biological Research (1999) 32: 155-162 Regulation of transgene expression 155 ISSN 0100-879X Regulation of transgene expression in genetic immunization J.S. Harms1, 1Department of Animal Health and Biomedical Sciences, University of Wisconsin, S.C. Oliveira2 Madison, WI, USA and G.A. Splitter1 2Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil Abstract Correspondence The use of mammalian gene expression vectors has become increas- Key words J.S. Harms ingly important for genetic immunization and gene therapy as well as · DNA vaccine AHABS basic research. Essential for the success of these vectors in genetic · Gene therapy 1655 Linden Drive · immunization is the proper choice of a promoter linked to the antigen Regulation Madison, WI 53706 · Transcription of interest. Many genetic immunization vectors use promoter elements USA · Transgene Fax: +1-608-262-7420 from pathogenic viruses including SV40 and CMV. Lymphokines E-mail: [email protected] produced by the immune response to proteins expressed by these vectors could inhibit further transcription initiation by viral promot- Research supported by the Robert ers. Our objective was to determine the effect of IFN-g on transgene Draper Technology Innovation Fund expression driven by viral SV40 or CMV promoter/enhancer and the (No. 135-0546) of the University mammalian promoter/enhancer for the major histocompatibility com- of Wisconsin, Madison. plex class I (MHC I) gene. We transfected the luciferase gene driven Presented at the International by these three promoters into 14 cell lines of many tissues and several Symposium “The Third Revolution species. -
RNA Viruses As Tools in Gene Therapy and Vaccine Development
G C A T T A C G G C A T genes Review RNA Viruses as Tools in Gene Therapy and Vaccine Development Kenneth Lundstrom PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland; [email protected]; Tel.: +41-79-776-6351 Received: 31 January 2019; Accepted: 21 February 2019; Published: 1 March 2019 Abstract: RNA viruses have been subjected to substantial engineering efforts to support gene therapy applications and vaccine development. Typically, retroviruses, lentiviruses, alphaviruses, flaviviruses rhabdoviruses, measles viruses, Newcastle disease viruses, and picornaviruses have been employed as expression vectors for treatment of various diseases including different types of cancers, hemophilia, and infectious diseases. Moreover, vaccination with viral vectors has evaluated immunogenicity against infectious agents and protection against challenges with pathogenic organisms. Several preclinical studies in animal models have confirmed both immune responses and protection against lethal challenges. Similarly, administration of RNA viral vectors in animals implanted with tumor xenografts resulted in tumor regression and prolonged survival, and in some cases complete tumor clearance. Based on preclinical results, clinical trials have been conducted to establish the safety of RNA virus delivery. Moreover, stem cell-based lentiviral therapy provided life-long production of factor VIII potentially generating a cure for hemophilia A. Several clinical trials on cancer patients have generated anti-tumor activity, prolonged survival, and -
Clone the Unclonable – Vectors and Cells to Capture and Express Problematic Dnas
Clone the Unclonable – Vectors and Cells to Capture and Express Problematic DNAs Ron Godiska, Ph.D. May, 2016 Agenda Improve Cloning and Expression of Problematic DNA • What makes DNA difficult to clone or express? • Circular vectors for difficult DNAs • Linear vectors for “impossible” DNAs • Enzyme-free cloning and compatible protein expression vectors • E. coli strains for toxic recombinant proteins or unstable DNA What is Unclonable DNA? Characteristics of Difficult DNA • Toxic coding sequences • Promoters • A-T Rich DNA • Large fragments (>10 kb) • Trace amounts Which types of difficult DNA have you worked with in the lab? Common Vector Traits Cause Cloning Problems Vector driven transcription into the insert – Deleterious expression – Destabilize 2o structure Insert driven transcription out into the vector – False negatives (blue or lethal) – Transcriptional interference pUC19 – Replication interference High copy number – Increased effect of the above issues – Active origin – Many copies/cell Supercoiling – Deletion of secondary structures CloneSmart® Technology “Silencing” DNA Inserts to Improve Cloning • No Transcriptional Interference – Stably maintain “unclonable” DNA • No blue/white screening – No false positives/negatives • Minimal vector size • Variable copy number • Variety of drug selection markers • Very low empty-vector background U.S. Patent 6,709,861 pSMART Vectors Clone Toxic Inserts and Promoters Test DNA Fragments: • RNase coding sequence (350 bp; no promoter) • Phage Lambda PR Promoter (400 bp) pSMART Vectors cDNA Clones are More Stable Deletion Rates: <1% in pSMART HC Kan vs. 32% in pUC % Deleted Clones Insert Size (kb) • Teleost fish cDNA library • Clones were grown in liquid medium, diluted, and regrown • Each final culture was diluted, plated, and grown up into individual colonies • Plasmid DNA was isolated from colonies for each clone and analyzed - Oleksiak M.F., Crawford D.L., 2001. -
Preamble This Document Compares Affinity Tools for The
1/8 Whitepaper “Affinity tools for the immunoprecipitation of GFP-fusion proteins” Preamble This document compares affinity tools for the immunoprecipitation of GFP-fusion proteins: • conventional anti-GFP antibodies, and • GFP-Trap®, a ready-to-use pulldown reagent that comprises an anti-GFP-Nanobody. What is the GFP-Trap? What are the differences between the ChromoTek GFP-Trap and conventional anti-GFP antibodies? How does the GFP-Trap have a superior performance for the immunoprecipitation of GFP-fusion proteins? Introduction of GFP as a protein-tag Green Fluorescent Protein (GFP) and variants are extensively used to study protein localization, interactions, and dynamics in cell biology. In many cases, data generated from microscopy studies requires complementary assays to obtain a more comprehensive set of information. Additional aspects including posttranslational modifications, DNA binding, enzymatic activity, and protein-protein interactions are investigated: Immunoprecipitation (IP), Co-IP, Co-IP for mass spectrometry (MS) analysis, and chromatin IP (ChIP) are used to complement microscopy measurements. Researchers now can apply GFP, GFP derivatives, and other fluorescent proteins using the constructs from microscopy analysis as epitope tags for reliable and sensitive biochemistry assays rather than re-cloning the genes coding for their protein of interest into vectors with traditional epitope tags. Furthermore, the performance of GFP-Trap makes GFP a first choice for biochemistry application. What is the GFP-Trap? The GFP-Trap Agarose is an anti-GFP-Nanobody covalently bound to agarose or magnetic agarose beads (Figure 1). It is used to immunoprecipitate GFP-fusion proteins from cell extracts of various organisms like mammals, plants, bacteria, fungi, insects, etc. -
Anti-E-Tag Mab-Magnetic Beads
M198-9 Page 1 For Research Use Only. P a Not for use in diagnostic procedures. g e Smart-IP Series 1 Anti-E-tag mAb-Magnetic beads CODE No. M198-9 CLONALITY Monoclonal CLONE 21D11 ISOTYPE Mouse IgG2a QUANTITY 20 tests (Slurry: 1 mL) SOURCE Purified IgG from hybridoma supernatant IMMUNOGEN KLH conjugated synthetic peptide, GAPVPYPDPLEPR (E-tag) REACTIVITY This antibody reacts with recombinant E-tagged protein. FORMURATION Covalently antibody conjugated 10 mg magnetic beads in 1 mL PBS/0.1% BSA/0.09% NaN3 *Azide may react with copper or lead in plumbing system to form explosive metal azides. Therefore, always flush plenty of water when disposing materials containing azide into drain. STORAGE This beads suspension is stable for one year from the date of purchase when stored at 4°C. APPLICATION-CONFIRMED Immunoprecipitation 50 L of beads slurry/sample For more information, please visit our web site http://ruo.mbl.co.jp/ MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. URL http://ruo.mbl.co.jp/ e-mail [email protected], TEL 052-238-1904 M198-9 Page 2 P a g PM020-7 Anti-DDDDK-tag-HRP-DirecT (polyclonal) RELATED PRODUCTS e PM020-8 Anti-DDDDK-tag-Agarose (polyclonal) Smart-IP series D291-3 Anti-His-tag (OGHis) (200 L) 3190 Magnetic Rack 2 D291-3S Anti-His-tag (OGHis) (50 L) M198-9 Anti-E-tag-Magnetic beads (21D11) D291-6 Anti-His-tag-Biotin (OGHis) M185-9 Anti-DDDDK-tag-Magnetic beads (FLA-1) D291-7 Anti-His-tag-HRP-DirecT (OGHis) D291-9 Anti-His-tag-Magnetic beads (OGHis) D291-8 Anti-His-tag-Agarose (OGHis) D153-9 Anti-GFP-Magnetic beads (RQ2) D291-A48 -
Important Vector Factors for Gene Expression Technical Reference Guide
BioResearch Important Vector Factors for Gene Expression Technical Reference Guide vectors expressing the same luciferase gene in different backbones and expression cassettes and obtained highly discriminative expres- sion levels. In this guideline, we show the most important aspects to be considered when choosing an expression vector and their impact on your experimental results. 1. Promoter Strength Introduction Is your promoter appropriate for the cell type that you are working with? Our Scientific Support Team is commonly asked: “Why don’t I get the Table 1 describes the promoter strengths as a relative percent of the same expression level of my gene if I use various vector backbones?” strength of the CMV promoter for various cells for which Lonza has There are many components to a vector that can have an effect on the Optimized Protocols. The CMV promoter activity is set to 100% based level of gene expression. Below you will find the 10 most important on their CAT assay values from the referenced publications. Although factors to consider when looking at vectors. CMV is a strong promoter in many mammalian cells, another promoter The selection of an appropriate expression vector is crucial for efficient may give stronger expression in your cells (e.g., promoter SV40 in gene expression. Just take a look at Figure 1. We tried 10 different BHK-21 cells). n 1600 1400 1200 1000 800 [% of pGL3-CMV at 24 h] 24 at pGL3-CMV [% of 600 400 Relative luciferase-expressio Relative 200 0 Control Program Only pGL3-Control pGL3-CMV pmax Cloning™ pSG5 pcDNA3.1 pFP pIRES-MCS B pcDNA4 HisMax pCMVbeta pCMV-TNT 4 hours 24 hours 48 hours n 2000 1500 1000 500 0 Control Program Only pGL3-Control pGL3-CMV pmax Cloning™ pSG5 pcDNA3.1 pFP pIRES-MCS B pcDNA4 HisMax pCMVbeta pCMV-TNT [% of pGL3-CMV at 24 h] 24 at pGL3-CMV [% of 4 hours 24 hours 48 hours Relative luciferase-expressio Relative Figure 1: Luciferase expression levels depend on vector backbones. -
Myc Tag Monoclonal Antibody
Myc tag Monoclonal Antibody Product Code CSB-MA000041M0m Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Immunogen EQKLISEEDL (Myc) synthetic peptide conjugate to KLH Raised In Mouse Species Reactivity N/A Tested Applications ELISA, WB, IF, IP; Recommended dilution: WB:1:500-1:5000, IF:1:100-1:300, IP:1:1000-1:1500 Relevance Myc tag is a polypeptide protein tag derived from the c-myc gene product that can be added to a protein. It can help to separate recombinant, overexpressed protein from wild type protein expressed by the host organism. Myc Tag also can be used to isolate protein complexes with multiple subunits. The Myc Tag Antibody is produced by the conjugation of a synthetic Myc tag peptide to KLH. Myc Tag Antibody can be used in various immunoassays, such as ELISA, Western blotting, immunoprecipitation, immunofluorescence, and more. Form Liquid Conjugate Non-conjugated Storage Buffer Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 Purification Method >95%, Protein G purified Isotype IgG1 Clonality Monoclonal Alias bHLHe39, c Myc, MRTL, MYC, Myc proto oncogene protein, MYC tag, Proto oncogene c Myc, Transcription factor p64 Product Type Monoclonal Antibody Target Names Myc tag Accession NO. 5F92F9 Image WB: Mouse anti Myc-tagged fusion protein Monoclonal antibody at 1.6µg/ml Lane 1: Recombinant Myc-tagged fusion protein at 50ng Lane 2: Recombinant Myc-tagged fusion protein at 25ng Lane 3: Recombinant Myc-tagged fusion protein at 12.25ng Lane 4: Recombinant Myc-tagged fusion protein at 6.25ng Lane 5: Recombinant Myc-tagged fusion protein at 3.125ng Lane 6: Recombinant Myc-tagged fusion protein at 1.5625ng 1 Secondary Goat polyclonal to Mouse IgG at 1/50000 dilution Predicted band size: 50 kd Observed band size: 50 kd Immunofluorescence staining of transfected HEK293 cells with CSB-MA000041M0m at 1:100, counter-stained with DAPI.